Evidence syntheses in the registry
140 documents of type evidence synthesis.
Documents
-
In the population defined for inflammatory bowel disease and mucosal barrier disorders, what is the incidence of adverse events leading to discontinuation with…
Moderate07 Sep 2026 -
In the population defined for obesity and overweight in adults, what is the effect of Survodutide compared with the comparator used in its contributing trials on the…
Moderate05 Sep 2026 -
How large is the discrepancy between labelled peptide mass and delivered peptide mass when counter-ion and water content are not reported?
High01 Sep 2026 -
What do published analytical surveys report about the identity, purity and content of peptides obtained from unregulated suppliers?
Low31 Aug 2026 -
In the population defined for growth hormone deficiency and growth-hormone secretagogue pharmacology, what is the effect of Gonadorelin compared with the comparator used…
Moderate29 Aug 2026 -
In the population defined for immune modulation and adjunctive immunotherapy, is the effect of Thymosin alpha-1 maintained across the full duration of the contributing…
Moderate26 Aug 2026 -
In the population defined for obesity and overweight in adults, what is the effect of Liraglutide compared with the comparator used in its contributing trials on the…
High20 Aug 2026 -
In adults with obesity, does a multi-receptor incretin agonist produce a larger reduction in body weight than a single glucagon-like peptide-1 receptor agonist?
Moderate19 Aug 2026 -
What is the effect of an amylin receptor agonist alone and in combination with a glucagon-like peptide-1 receptor agonist on body weight?
Moderate10 Aug 2026 -
In the population defined for type 2 diabetes mellitus, what is the effect of Exenatide compared with the comparator used in its contributing trials on the anchor…
High28 Jul 2026 -
In the population defined for obesity and overweight in adults, what is the effect of Mazdutide compared with the comparator used in its contributing trials on the…
Moderate18 Jul 2026 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the effect of Semaglutide compared with the comparator…
High04 Jul 2026 -
What randomised human evidence exists for BPC-157 in any indication?
Very low03 Jul 2026 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, is the effect of Exenatide maintained across the full duration of…
High25 Jun 2026 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Semaglutide compared with its comparator?
High18 Jun 2026 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Retatrutide compared with its comparator?
Moderate12 Jun 2026 -
In the population defined for cutaneous wound healing and tissue repair, what is the effect of Thymosin beta-4 compared with the comparator used in its contributing…
Low10 Jun 2026 -
In the population defined for immune modulation and adjunctive immunotherapy, what is the effect of Thymosin alpha-1 compared with the comparator used in its…
Moderate09 Jun 2026 -
In the population defined for hypoactive sexual desire and erectile dysfunction, what is the incidence of adverse events leading to discontinuation with PT-141…
Moderate05 Jun 2026 -
In the population defined for type 2 diabetes mellitus, what is the effect of Tirzepatide compared with the comparator used in its contributing trials on the anchor…
High02 Jun 2026 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Mazdutide compared with its comparator?
Moderate02 Jun 2026 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Lixisenatide compared with its comparator?
High31 May 2026 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the incidence of adverse events leading to…
Moderate22 May 2026 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Dulaglutide compared with its comparator?
High21 May 2026 -
How much does a reported chromatographic purity figure vary with the method used to obtain it?
High20 May 2026 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Semaglutide, oral compared with its…
High19 May 2026 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Mazdutide compared with its…
Moderate18 May 2026 -
In the population defined for type 2 diabetes mellitus, is the effect of Tirzepatide maintained across the full duration of the contributing trials?
High16 May 2026 -
For neuropeptides holding a national marketing registration outside the jurisdictions the Institute routinely reviews, what evidence is retrievable and what can be…
Very low13 May 2026 -
In the population defined for type 2 diabetes mellitus, is the effect of Dulaglutide maintained across the full duration of the contributing trials?
High12 May 2026 -
In the population defined for type 2 diabetes mellitus, what is the effect of Retatrutide compared with the comparator used in its contributing trials on the anchor…
Moderate10 May 2026 -
In the population defined for obesity and overweight in adults, is the effect of Survodutide maintained across the full duration of the contributing trials?
Moderate10 May 2026 -
In adults with type 2 diabetes and chronic kidney disease, what is the effect of a glucagon-like peptide-1 receptor agonist on kidney outcomes?
High07 May 2026 -
In the population defined for adjunctive therapy in type 1 diabetes, what is the incidence of adverse events leading to discontinuation with Liraglutide compared with…
Moderate07 May 2026 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Orforglipron compared with its comparator?
Moderate05 May 2026 -
In the population defined for type 2 diabetes mellitus, is the effect of CagriSema (cagrilintide with semaglutide) maintained across the full duration of the…
Moderate02 May 2026 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Tirzepatide compared with its…
High26 Apr 2026 -
In the population defined for type 2 diabetes mellitus, is the effect of Orforglipron maintained across the full duration of the contributing trials?
Moderate21 Apr 2026 -
In the population defined for type 2 diabetes mellitus, what is the effect of Liraglutide compared with the comparator used in its contributing trials on the anchor…
High20 Apr 2026 -
In the population defined for growth hormone deficiency and growth-hormone secretagogue pharmacology, what is the incidence of adverse events leading to discontinuation…
Low17 Apr 2026
page 1 of 4